JP7017563B2 - Ｐｐａｒアゴニスト化合物の結晶性および塩形態 - Google Patents

Ｐｐａｒアゴニスト化合物の結晶性および塩形態 Download PDF

Info

Publication number
JP7017563B2
JP7017563B2 JP2019518286A JP2019518286A JP7017563B2 JP 7017563 B2 JP7017563 B2 JP 7017563B2 JP 2019518286 A JP2019518286 A JP 2019518286A JP 2019518286 A JP2019518286 A JP 2019518286A JP 7017563 B2 JP7017563 B2 JP 7017563B2
Authority
JP
Japan
Prior art keywords
disease
compound
hemisulfate
syndrome
pparδ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529516A (ja
JP2019529516A5 (enExample
Inventor
ラグ，バーラト
トルザスカ，スコット
Original Assignee
ミトブリッジ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミトブリッジ，インコーポレーテッド filed Critical ミトブリッジ，インコーポレーテッド
Publication of JP2019529516A publication Critical patent/JP2019529516A/ja
Publication of JP2019529516A5 publication Critical patent/JP2019529516A5/ja
Application granted granted Critical
Publication of JP7017563B2 publication Critical patent/JP7017563B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2019518286A 2016-10-05 2017-10-05 Ｐｐａｒアゴニスト化合物の結晶性および塩形態 Active JP7017563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404474P 2016-10-05 2016-10-05
US62/404,474 2016-10-05
PCT/US2017/055403 WO2018067860A1 (en) 2016-10-05 2017-10-05 Crystalline and salt forms of ppar agonist compounds

Publications (3)

Publication Number Publication Date
JP2019529516A JP2019529516A (ja) 2019-10-17
JP2019529516A5 JP2019529516A5 (enExample) 2020-10-22
JP7017563B2 true JP7017563B2 (ja) 2022-02-08

Family

ID=60153508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019518286A Active JP7017563B2 (ja) 2016-10-05 2017-10-05 Ｐｐａｒアゴニスト化合物の結晶性および塩形態

Country Status (30)

Country Link
US (3) US10927094B2 (enExample)
EP (1) EP3523283B1 (enExample)
JP (1) JP7017563B2 (enExample)
KR (1) KR20190057129A (enExample)
CN (1) CN109843857B (enExample)
AU (1) AU2017340763B2 (enExample)
CA (1) CA3036587A1 (enExample)
CO (1) CO2019003162A2 (enExample)
CY (1) CY1124655T1 (enExample)
DK (1) DK3523283T3 (enExample)
ES (1) ES2887008T3 (enExample)
HR (1) HRP20211341T1 (enExample)
HU (1) HUE055678T2 (enExample)
IL (1) IL265730B (enExample)
JO (1) JOP20190039B1 (enExample)
LT (1) LT3523283T (enExample)
MA (1) MA46460A (enExample)
MX (1) MX385973B (enExample)
MY (1) MY202008A (enExample)
PH (1) PH12019500727A1 (enExample)
PL (1) PL3523283T3 (enExample)
PT (1) PT3523283T (enExample)
RS (1) RS62245B1 (enExample)
RU (1) RU2759724C2 (enExample)
SG (1) SG11201901995TA (enExample)
SI (1) SI3523283T1 (enExample)
TW (1) TWI769182B (enExample)
UA (1) UA124770C2 (enExample)
WO (1) WO2018067860A1 (enExample)
ZA (1) ZA201901744B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
AU2016333963C1 (en) * 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN109843857B (zh) 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
CN112714762A (zh) * 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
JP7397491B2 (ja) * 2018-10-23 2023-12-13 国立研究開発法人科学技術振興機構 ＰＰＡＲδ活性化剤
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2022256540A1 (en) 2021-06-02 2022-12-08 Astellas Pharma Inc. Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
WO2025207099A1 (en) * 2024-03-28 2025-10-02 Astellas Pharma Inc. Ppar-delta inhibitors for preventing post-operative atrial fibrillation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057658A1 (en) 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
JP2018534355A (ja) 2015-10-07 2018-11-22 ミトブリッジ，インコーポレーテッド Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
JP2019511527A (ja) 2016-04-13 2019-04-25 ミトブリッジ，インコーポレーテッド Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
JP2019533660A (ja) 2016-10-05 2019-11-21 ミトブリッジ，インコーポレーテッド 急性腎障害を処置する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241157A1 (en) 2003-01-06 2006-10-26 Conner Scott E Heterocyclic ppar modulators
EP1671633A1 (en) 2004-12-17 2006-06-21 Sanofi-Aventis Deutschland GmbH Use of PPAR agonists for the treatment of congestive heart failure
CN101141957A (zh) * 2005-02-03 2008-03-12 Irm责任有限公司 作为ppar调节剂的化合物和组合物
CN101296892A (zh) * 2005-09-07 2008-10-29 普莱希科公司 Ppar活性化合物
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
CN102727489A (zh) * 2012-07-18 2012-10-17 西南大学 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用
CN109843857B (zh) 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057658A1 (en) 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
JP2018534355A (ja) 2015-10-07 2018-11-22 ミトブリッジ，インコーポレーテッド Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
JP2019511527A (ja) 2016-04-13 2019-04-25 ミトブリッジ，インコーポレーテッド Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
JP2019533660A (ja) 2016-10-05 2019-11-21 ミトブリッジ，インコーポレーテッド 急性腎障害を処置する方法

Also Published As

Publication number Publication date
CO2019003162A2 (es) 2019-05-21
US20210171494A1 (en) 2021-06-10
CN109843857B (zh) 2023-01-06
RU2019110736A (ru) 2020-11-06
RU2019110736A3 (enExample) 2021-02-05
RS62245B1 (sr) 2021-09-30
ZA201901744B (en) 2021-10-27
MX385973B (es) 2025-03-18
CA3036587A1 (en) 2018-04-12
US11912681B2 (en) 2024-02-27
PT3523283T (pt) 2021-09-10
DK3523283T3 (en) 2021-06-28
KR20190057129A (ko) 2019-05-27
US20230257360A1 (en) 2023-08-17
BR112019006030A2 (pt) 2019-06-18
HUE055678T2 (hu) 2021-12-28
JP2019529516A (ja) 2019-10-17
SI3523283T1 (sl) 2021-11-30
SG11201901995TA (en) 2019-04-29
EP3523283A1 (en) 2019-08-14
MY202008A (en) 2024-03-28
CN109843857A (zh) 2019-06-04
US11530192B2 (en) 2022-12-20
MA46460A (fr) 2021-03-17
AU2017340763A1 (en) 2019-03-28
US20200181108A1 (en) 2020-06-11
WO2018067860A1 (en) 2018-04-12
RU2759724C2 (ru) 2021-11-17
AU2017340763B2 (en) 2021-10-07
LT3523283T (lt) 2021-07-12
JOP20190039A1 (ar) 2019-03-07
ES2887008T3 (es) 2021-12-21
PL3523283T3 (pl) 2021-12-13
MX2019003945A (es) 2019-09-18
CY1124655T1 (el) 2022-07-22
HRP20211341T1 (hr) 2021-11-26
IL265730B (en) 2022-09-01
US10927094B2 (en) 2021-02-23
EP3523283B1 (en) 2021-06-09
TW201827409A (zh) 2018-08-01
UA124770C2 (uk) 2021-11-17
TWI769182B (zh) 2022-07-01
PH12019500727A1 (en) 2019-07-29
JOP20190039B1 (ar) 2023-03-28
IL265730A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
US11912681B2 (en) Crystalline and salt forms of PPAR agonist compounds
NL1031976C2 (nl) N-(pyridine-2-yl)sulfonamidederivativen.
JP2022521825A (ja) アンドロゲン受容体モジュレーター及びタンパク質分解誘導キメラリガンドとして使用するための方法
EP3442948B1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
JP2020075939A (ja) Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
BRPI0814065B1 (pt) Derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
BRPI0414130B1 (pt) Compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem
TWI592407B (zh) 飢餓素ｏ－醯基轉移酶抑制劑
TW201639823A (zh) 軸手性異構體及其製備方法和製藥用途
JP6937524B2 (ja) アミド化合物およびその使用
HK40006508B (en) Crystalline and salt forms of ppar agonist compounds
BR112019006030B1 (pt) Formas cristalinas e de sal de compostos agonistas de ppar e seus usos
HK40006508A (en) Crystalline and salt forms of ppar agonist compounds
TW202613096A (zh) 氘代的Ｈｅｄｇｅｈｏｇ通路ＳＭＯ受體抑制劑
EA039771B1 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200910

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210719

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220127

R150 Certificate of patent or registration of utility model

Ref document number: 7017563

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250